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Área de estudio: Farmacia.  
 
Propósito y Método de Estudio: La aplicación exitosa de complejos metálicos en 
el tratamiento de numerosas enfermedades, como el cáncer,  es un área 
en plena expansión en química biomédica e investigaciones. Estudios de 
compuestos organoestánicos, muestran la versatilidad y las atractivas 
características de estas moléculas. A su vez, se ha reportado el desarrollo 
de nuevos compuestos a partir de bezoilhidrazinas, las cuales poseen el 
fragmento azometino (-N=CH-), pilar clave para el diseño de nuevos 
fármacos con actividad biológica. Con base en lo anterior, estamos 
interesados en realizar la síntesis de cuatro compuestos de estaño 
derivados de benzohilidrazonas, y determinar su capacidad citotóxica. 
 
Contribuciones y Conclusiones: En este trabajo de investigación se reportaron 
cuatro nuevas estructuras de compuestos de estaño derivados de 
benzoilhidrazinas, los cuales fueron caracterizados mediante diversas 
técnicas espectroscópicas y espectrométricas, así como difracción de 
rayos X. De igual forma la capacidad citotóxica de cada compuesto fue 
estudiada y comparada con fármacos metalados como cisplatino y 
carboplatino. Y en algunos casos fue posible el uso de su capacidad 
luminiscente para estudiar su comportamiento intracelular.  
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Study area: Pharmacy.  
 
Purpose and study method: The successful application of metal complexes in 
the treatment of many diseases, including cancer, is a rapidly expanding 
area in biomedical chemistry and research. Organotin compounds studies 
show the versatility and the attractive features of these molecules. In the 
same manner, has been reported the development of new compounds 
derivative from bezoylhidrazones, which possess the azomethine fragment 
(-N = CH-), key pillar for designing new drugs with biological activity. Based 
on the above, we are interested in to synthesize four tin compounds 
derivatives from benzoylhidrazones, and the evaluation of their cytotoxic 
capacity. 
 
Conclusions and contribution: In this research work, we reported four new tin 
compounds derivatives from bezoylhidrazones, which were characterized 
by spectroscopic and spectrometric techniques and X-ray diffraction In the 
same manner, cytotoxic ability of each compound was studied and 
reported and compared with metaled base drugs like cisplatin and 
carboplatin. Also, in some cases it was possible to use their luminescent 
ability to study their intracellular behavior.  
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1. INTRODUCTION 
 
"Cancer" is a generic term that encompasses a large group of diseases 
that develop as a result of abnormalities in the genetic material of cells and can 
affect any part of the body; is also spoken of "malignant tumors" or 
"malignancies". A feature of cancer is the rapid multiplication of abnormal cells 
that extend beyond their usual limits and can invade adjacent parts of the body 
or spread to other organs, a process known as metastasis (Figure 1). 
 
 
 
 
 
Figure 1. Rapid multiplication of cancer cells. 
 
In an observation on a global scale, cancer is one of the major causes of 
deaths, is responsible for one in every eight deaths throughout the world.i 
According to the WHO (World Health Organization) this disease is attributed 
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about 7.6 million deaths (approximately 13% of the total) that occurred 
worldwide in 2008. ii 
 
It encompasses more than 100 different diseases with different risk factors 
and epidemiology that originate from the majority of cell types and organs of the 
human body. It is known that cancer can be caused by external factors (snuff, 
chemicals, radiation and infectious organisms) and internal factors (inherited 
mutations, hormones, immune conditions and mutations that occur from the 
metabolism) (Scheme 1). These causal factors may act together or in sequence 
to initiate or promote carcinogenesis. The development of most types of cancer 
requires multiple steps that take place over many years.iii 
 
 
 
 
Scheme 1. Factors that may favor the development of cancer. 
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Genetic abnormalities found in cancer cells may consist of a point 
mutation, translocation, amplification, deletion, and gain or loss of an entire 
chromosome. There are genes that are more likely to suffer mutations that 
trigger cancer. These genes, when in its normal state, are called proto-
oncogenes, and when mutated are called oncogenes. What these genes usually 
encode are growth factor receptors, so that genetic mutation renders produces 
receptors to be permanently activated or encoding growth factors themselves, 
and the mutation can cause growth factors to be produced in excessive and 
uncontrolled manner.iv 
 
The tissue from which cancer cells originate classifies Cancer. The type of 
tumor and the extent of disease largely influence the diagnosis. Often in early 
stages, symptoms may be interpreted as originating from other pathologies. 
Although the first manifestations of the disease come from symptoms, blood 
tests or X-rays, definitive diagnosis requires histological examination under a 
microscope. The histological classification after biopsy of the lesion is used to 
determine the most appropriate treatment. The treatment options depend mainly 
on the type of cancer that is suffering from well as the status, taking into account 
other individual factors such as age, general condition, patient preferences, etc.v 
 
For cancer treatment careful selection of one or more therapeutic 
modalities, surgery, radiotherapy or chemotherapy is required. The goal of each 
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one of them is to cure the disease, or significantly prolong the survival and 
possibly improve the quality of life for patients. 
 
The applications of appropriate treatments that combine surgery, 
radiotherapy and chemotherapy have allowed improving greatly on the quality of 
life for cancer patients and to lower mortality. 
 
Although surgery continues to be the primary treatment in our days has 
managed to be less radical and this is largely due to the use of radiotherapy, 
which can eliminate the tumor mass with great precision and once unthinkable 
power. However, this form of therapy is local and only has an effect if malignant 
cells are located within the irradiated field, is ineffective in combating metastasis. 
Here comes into play its role chemotherapy, which is the third weapon with 
which they have to fight cancer. 
 
It is known that chemotherapy is the treatment with drugs that can destroy 
these cells or stop them from dividing (Figure 2). However, one of the major 
situations that arise against them is the fact that it can also damage healthy 
cells, causing the so-called side effects. 
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Figure 2.General action of drugs in cancer treatment. 
 
Chemotherapy is used to treat many types of cancer. Currently more than 
100 chemotherapy drugs are used, either on their own or in combination with 
other medications or treatments. As the investigations continue, it is expected to 
have more drugs available. These drugs vary widely in their chemical 
composition, the way they are administered, their usefulness in treating specific 
forms of cancer and its side effects.  
 
Antitumor drugs act on cell division by inhibiting or hindering, but these 
preparations have the disadvantage that they do not act on a selective basis and 
do not interact with the neoplastic cells only, but rather attack the healthy 
dividing ones, such as red blood cells, platelets, hair follicles, mucosal, and so 
on. Therefore patients receiving chemotherapy lose their hair, suffer 
immunosuppressive conditions, mucosal inflammation and ulcers in the mouth. 
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Yet the great workhorse of chemotherapists is in the ability of cancer cells to be 
invulnerable to drugs that interfere with the cellular division.  
 
Since the introduction of cisplatin (Figure 3) in cancer therapy, metal 
complexes and organometallic compounds have been gaining increasing 
importance in oncology. The impressive clinical effectiveness of cisplatin is 
limited by significant side effects and the appearance of drug resistance. 
Therefore, new Pt (II) and Pt (IV) complexes have been introduced in therapy or 
are currently in advanced clinical trials. Furthermore, have been developed 
innovative non-platinum metal based antitumor agents whose activity are not 
dependent on direct DNA damage and may involve proteins and enzymes. 
Derivatives of gold and tin are enjoying a growing interest and look very 
promising as potential drug candidates.vi 
 
 
Figure 3.Molecular structure of cisplatin. 
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2. BACKGROUND 
 
2.1 Antineoplastic Drugs. 
 
There are many ways to induce irreparable DNA damage, which can cause 
the detention of its replication and create the conditions to induce cellular 
apoptosis.  
 
Chemotherapy drugs can be divided into several groups based on factors 
such as their mechanism of action, its chemical structure and its relationship 
with other medicines. Since some medications work in more than one way, they 
may belong to more than one group. It is important to know the mechanism of 
action of a medicinal product to predict side effects. This helps oncologists 
decide which medications may work well in combination. 
 
2.2 Types of Drug–DNA interaction. 
 
There are primarily three different ways by which anticancer drugs interact 
with DNA vii (Scheme 2):  
 
• Through control of transcription factors and polymerases. Here, 
the drugs interact with proteins that bind to DNA. 
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• Through RNA binding to DNA double helix to form nucleic acid 
triple helix structures or RNA hybridization (sequence specific binding) to 
exposed DNA single strand forming DNA–RNA hybrids that may interfere 
with transcriptional activity. 
• Through binding of small aromatic ligand molecules to DNA double 
helical structures. The binding of small molecules to DNA involves 
electrostatic interaction, intercalation between base pairs and minor and 
major DNA grooves binding interaction.  
 
 
Scheme 2. Summary of mechanisms of action of anticancer drugs viii 
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2.3 Metal based drugs. 
 
The successful application of metallic complexes in the treatment of many 
human diseases is a rapidly expanding area in biomedical chemistry and 
researches, which undoubtedly help to improve the quality of life. Cancer is one 
of the primary objectives of scientific research in the area of drug development, 
as it is one of the leading causes of premature deaths around the world. 
 
Several efforts have been carried out to find useful treatments for cancer, 
since 1969 Rosenberg reports on the cytostatic activity of a synthetic compound 
of inorganic origin that set the standard for a new series of compounds: Cisplatin 
(cis-diamine-dichloro platinum (II)). Many tumors are refractory to this and 
therefore the search for new compounds began with the following 
characteristics:  
 
• Absence of cross-resistance  
• Wider spectrum of activity  
• Higher antitumor clinical effectiveness  
• Reduction of emetic and kidney effects  
• Synergism in combined therapies. 
 
Experimental evidence has demonstrated that cisplatin coordination 
compounds with antineoplastic activity satisfy the following assumptions: With 
	  	   10	  
the discovery of cis-diamminedichloroplatinum (II) in the sixties it has been 
observed that the metallic compound acts as the focal point for proteins nucleic 
acids of cancer cells and it has been proposed that the method of action of 
cisplatin is similar to an intercalating agent or alkylating and is directly linked to 
the nitrogen of the 7-position of guanine in DNA. ix 
 
The investigation has shown that the most effective coordination 
compounds used as anticancer medicines, based on DNA binding, are cisplatin, 
oxaliplatin, carboplatin and nedaplatin, which are metalocomplexes platinum 
(II)x. These medications revolutionized chemotherapy as from the late seventies 
to be active against resistant tumors commercial drugs. Despite its high activity, 
the application of cisplatin and similar compounds has significant disadvantages 
which include: poor water solubility, severe side effects that are typical of the 
heavy metal toxicity, and the development of drug tolerance from the tumor. The 
last two are the main driving force behind the current research in the field of 
development of new anticancer agents. 
 
The investigations of compounds with other metals (Ti, Ga, Ge, Pd, Au, 
Co, and Sn) are currently ongoing which may help prevent, or improve, the 
problems associated with the use of platinum compounds as therapeutic 
agents.xi  Indirect ionizing radiation causes DNA damage by reactive oxygen 
species, while chemotherapy uses chemical substances that interact directly 
with DNA. (Figure 4) 
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Figure 4. Mechanism of action proposed for organometallic compounds. xi 
 
2.4 Organotin compounds. 
 
The value of the organotin compounds (IV) resides in its wide range of 
applications such as stabilizers in PVC (polyvinyl chloride) in antifouling paints 
and coatings for the protection of ship hulls and as precursors of SnO2 in glass 
coating xii  in electro luminescence with the manufacturing of OLEDS (Organic 
Light-Emitting Diode),xiii  its use in the design of sensors that selectively respond 
to the presence of an analyte in particular xiv  as well as studies of biological 
activity of these molecules, which have proved their antifungal and antibacterial 
properties. xv  Currently organometallic tin compounds are latent alternative as 
chemotherapeutic agents, anticancer who show acceptable antiproliferative 
activity in vitro and in vivo.xvi 
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The structural diversity of the compounds and their applications, 
particularly the cytotoxic activity, have been a major impetus for the investigation 
of these molecules. xvii  
 
It is well known that the biochemical activity of organotin compounds is 
influenced by the structure of the molecule and the coordination number of tin 
atoms. It has been determined that the nature of the binder does not affect the 
toxicity with the exception that it itself is toxic. The ability to bind to DNA 
depends on the coordination number and nature of the groups attached to the 
tin atom. DNA phosphate usually acts as the anchoring site. With a coordination 
number of 5 tin forms a dense positive core is attracted to the negatively 
charged phosphate. 
 
2.5 Tin compounds as cytotoxic. 
 
The antitumor properties of tin complexes have been established since 
1929. In 1980 Crowe xviii  et. al. reported the anticancer characteristics of 
organotin complexes. Gielen published a series of research articles on this 
subject over the past two decades. They synthesized a series of water-soluble 
organotin complexes and investigated their anticancer activities. They found that 
the anticancer activities of these organotin complexes were 100 times higher 
than that of carboplatin and cisplatin used in clinical applications xix. Since then, 
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many researchers have shown great interest in this field and published reviews 
of progress on the detection of potential antitumor organotin compounds. 
 
Organic tin compounds that exhibit potent anticancer activity can act 
through different mechanisms at the molecular level.xx Induced cytotoxicity of 
organic tin compounds has been associated with several mechanisms: inhibition 
of macromolecular synthesis, altered mitochondrial energy metabolism, 
reduction of DNA synthesis and direct interaction with the cell membrane 
leading to an increase calcium concentration. The promotion of oxidative 
damage in DNA were detected in vivo. xxi 
 
The most recent use of the different organic derivatives of tin (IV) has 
shown an acceptable in vitro cytotoxicity and in vivo antiproliferative activity as 
new chemotherapy agents. xxii  Also, organic complexes of tin (IV) have other 
attractive features such as increased water solubility, toxicity in general tends to 
be less than the platinum drugs, best possible removal of body, a reduction in 
the case side effects and no emetogenesis. However, the most important point 
of organotin compounds is the fact that these do not develop tolerance that 
generates cisplatin and its analogs. xxiii  Additionally, it has been well established 
that organotin (IV) compounds are involved in cancer chemotherapy because of 
their apoptotic inducing property . xxiv 
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2.6 Tin complexes derivative from benzoylhydrazine. 
 
Lately new compounds with biological activity have been developed from 
bezoylhidrazines. These molecules possess the azomethine fragment               
(-N = CH), which is the key to the design of new drugs with anticonvulsant, 
antidepressant, analgesic, anti-inflammatory and anti-malarial activity xxv. Their 
analysis has been a pattern to develop new hydrazones with diverse biological 
activity. It has been described the synthesis of tin complexes derivatives of 
benzoylhydrazines ligands either penta- (I-IV) xxvi  or six-coordinated (V-VII), xxvii  
which was characterized in solution and their molecular structure was 
elucidated. In turn, these compounds have high thermal stability to air and 
moisture. (Figure 5) 
 
 
 
Figure 5. Penta and hexacoordinated organotin compounds derived from 
benzoylhydrazine. 
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3.HYPOTHESIS AND OBJECTIVES. 
 
3.1 Hypothesis. 
 
Pentacoordinated organotin compounds derived from benzoylhydrazine 
have a cytotoxic effect on neoplastic cell lines in culture. 
 
 
3.2 General Objective. 
 
Synthesize, characterize four new tin compounds derived from 
benzoylhydrazines and test its cytotoxic effect on neoplastic cell lines in culture. 
 
 
3.2.1 Specific Objectives. 
 
• Synthesize four new benzoylhydrazine tin compounds by a conventional 
method. 
 
• Spectroscopy (1H, 13C, 119Sn NMR; IR) and optically (UV-vis, 
fluorescence) characterization of synthesized compounds. 
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• Obtain appropriate crystals and set the crystal structure through X-ray 
diffraction. 
 
• Perform biological cytotoxicity assays in normal and cancer cell lines. 
 
• Carry out biological cytotoxicity assays in murine melanoma line. 
 
• Explore the possibility of using the fluorescence property of tin 
compounds derived from benzoylhydrazines in cell staining using a 
murine melanoma line. 	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4. MATERIALS AND METHODS 
 
4.1 Materials. 
 
4.1.1 Synthesis and characterization  
 
All starting materials were purchased from Sigma-Aldrich Chemical 
Company. Solvents were used without further purification.  
 
Melting points were determined on an Electrothermal Mel-Temp apparatus, 
and are not corrected. Infrared spectra were recorded using a Burker Tensor 27-
FT-IR spectrophotometer equipped with a Pike Miracle TM ATR accessory with a 
single reflection ZnSe ATR cristal.  
 
Multinuclear magnetic resonance experiments as 1H, 13C, and 119Sn- NMR 
spectra were recorded on a Bruker advance DPX 400. Chemical shifts (ppm) 
are relative to (CH3)4Si for 1H and 13C, and 119Sn-NMR spectra were referenced 
externally to (CH3)4Sn. Mass spectra were recorded on an AB Sciex API 2000 
TM LC/MS/MS System.  
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Elemental analyses were carried out on a Thermo Finngan Flash EA 1112 
elemental microanalyzer. High resolution mass spectra were acquired by 
source. UV-Vis absorption spectra were measured on a Shimadzu 2401 PC 
spectrophotometer. The emission spectra have been recorded with a Fluorolog 
3 spectrofluorometer, by exciting 10 nm below the longer wavelength absorption 
band. 
 
 The X-ray data for the compounds 1-4 were covered with a layer of 
hydrocarbon oil that was selected and mounted with paratone-N oil on a cryo-
loop, and inmediately placed in the low-temperature nitrogen stream at 100(2) K. 
The data for the compounds were recorded on a Bruker SMART APEX CCD 
area detector system equipped with a Oxford Cryosystems 700 Series 
Cryostream cooler, a graphite monochromator, and a Mo Kα fine-focus sealed 
tuve (λ=0.71037 Å). The structures were solved by direct methods using 
SHELXS-97 and refined against F2 on all data by full-matrix least-squares with 
SHELXS-97. Absorption corrections were applied by using SADABS.  
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4.1.2 Bioassays 
 
To perform the in vitro studies we used three different cell lines (Table 1): 
 
TABLE 1 
List of cell lines used in cytotoxicity assays. 
 
Cell line #ATCC Organism Tissue Morphology 
HGF1 CRL-2014 Human Gingival biopsy Fibroblast 
A375 CRL-1619 Human Skin Epithelial 
B16F10 CRL-6475 Mouse Skin Spindle-shaped and 
epithelial-like cells 
 
 
The culture medium used was DMEM and DMEM/F12, both supplemented 
with 5% fetal bovine serum and 1x antibiotic-antimycotic, all purchased from 
GIBCO Invitrogen Life Technologies. Other reactants used were 0.25% Trypsin-
EDTA (1X), antibiotic-antimycotic (100x), purchased from GIBCO Invitrogen Life 
Technologies. Alamar blue used for the metabolic viability assay from Biosource 
Invitrogen Life Technologies. Neutral Red solution as a vital stain to stain living 
cells, from Sigma-Aldrich. 
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Equipment: 
• Incubator for cell culture model 3554 Thermo Electron Corporation. 
• Bell laminar flow biosafety Nuaire A-425-400 model. 
• ELISA plate reader Labsystems Multiskan model  ELx800. 
• Confocal microscope TCS SP5 model  Leica. 
 
4.2 Methods.  
 
4.2.1 Synthesis procedure of compounds 1-4. 
 
 
 
 
 
Scheme 3. Synthesis procedure of compounds 1-4. 
 
	  	   21	  
4.2.1.1 [N-(3-methoxy-6-benzylidene)-benzyhydrazidato] diphenyltin (IV). (1) 
 
A solution of 2-hydroxy-4-
methoxybenzaldehyde (0.15g, 1mmol), 
benzoic hydrazide (0.13g, 1mmol), and 
di-phenyltin oxide (0.29g, 1mmol) in 
benzene (50 ml) was heated to reflux for 
24 hr in a Dean-Stark apparatus used 
for the azeotropic removal of water and allowed to cool to room temperature. 
Then, all volatiles were removed under vacuum. Yield: 83%. Yellow solid. 
MP:165 ºC. 1H NMR (400.13 MHz, CDCl3, 298 K) δ: 3.90 (s, 3H, H-15), 6.39 
(dd, 1H, 3J = 8 Hz, 2 Hz ,H-5), 6.58 (d, 1H, J= 2 Hz, H-2), 7.09 (d, 1H, 3J = 8 Hz, 
H-4), 7.42 (m, 6H, H-m, H-p), 7.48 (m, 3H, H-11, H-12, H-13),  7.89, (m, 4H, 3J 
(1H-119/117Sn) =84/72 Hz ,H-o), 8.22 (d, 2H, 3J = 8 Hz, H-10, H-14), 8.67 (s, 1H, 
3J (1H-119Sn)  = 54 Hz, H-7).13C NMR (100.61 MHz, CDCl3, 298 K) δ: 55.66 (C-
15), 104.42 (C-2) , 107.65 (C-5), 111.05 (C-6), 127.73 (C-10,14), 128.40 (C-
11,13), 128.98 (C-m), 130.58 (C-p), 131.13 (C-12), 133.54 (C-9), 135.99 (C-4), 
136.36 [C-o, 2J (13C-119Sn) = 54 Hz], 139.46 (C-i), 161.04 (C-7), 166.43 (C-3), 
168.26 (C-8), 169.87 (C-1). COSY correlation [δH/δH]: 6.39/6.58 (H-4/H-2), 
6.39/7.09 (H-4/H-5), 7.42/7.89 (H-m, H-p/H-o), 7.48/8.22 (H-11, H-12, H-13/H-
10, H-14). HETCOR correlation [δH/δC]: 3.90/55.66 (H-15/C-15), 6.39/107.65 
(H-4/C-4), 6.58/104.42 (H-2/C-2), 7.09/135.99 (H-5/C-5), 7.42/128.98 (H-m/C-
m), 7.42/130.58 (H-p/C-p), 7.48/128.40 (H-11, H-13/C-11, C-13), 7.48/131.13 
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(H-12/C-12), 7.89/136.36 (H-o/C- o), 8.22/127.73 (H-10, H-14/C-10, C-14), 
8.67/161.04 (H-7/C-7). 119Sn NMR (149 MHz, CDCl3, ppm, 298 K) δ: - 330.31. 
IR-ATR νmax cm-1: 3090, 1600 (C=N), 1200, 1050, 770. UV/Vis: λmax (nm) = 
402 (CHCl3, 1x10-3 M). TOF calc. for [(C27H23N2O3Sn+H)+] : 543.072518; 
Found: 543.072624 (error = 0.194677 ppm). 
 
4.2.1.2 [N-(2,4-di-tert-butyl-6-benzylidene)-benzyhydrazidato] 
diphenyltin(IV). (2) 
 
A solution of 3,5-di-tert-butyl-2-
hydroxybenzaldehyde (0.23g, 1mmol), 
benzoic hydrazide (0.13g, 1mmol), and di-
phenyltin oxide (0.29g, 1mmol) in benzene 
(50 ml) was heated to reflux for 24 hr in a 
Dean-Stark apparatus used for the 
azeotropic removal of water and allowed to cool to room temperature. Then, all 
volatiles were removed under vacuum. Yield: 75%. Yellow solid. MP:158 ºC. 1H 
NMR (400.13 MHz, CDCl3, 298 K) δ: 1.31 (s, 9H, H-18), 1.53 (s, 9H, H-16), 7.03 
(s, 1H, H-5), 7.40 (m, 6H, H-m, H-p), 7.47 (m, 3H, H-11, H-12, H-13), 7.56 (d, 
1H, H-3) ,  7.86, (m, 4H, 3J (1H-119/117Sn) =84/68 Hz ,H-o), 8.21 (dd, 2H, 3J = 8 
Hz, 4 Hz, H-10, H-14), 8.83 (s, 1H, 3J (1H-119Sn)  = 56 Hz, H-7).13C NMR (100.61 
MHz, CDCl3, 298 K) δ: 30.22 (C-16), 31.43 (C-18) , 34.16 (C-17), 35.63 (H-15), 
116.40 (C-6), 127.84 (C-10,14), 128.38 (C-11,13), 128.91 (C-m), 129.05 (C-5), 
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130.49 [C-p, 4J (13C-119Sn) = 17 Hz], 131.12 (C-3), 131.23 (C-12), 133.48 (C-9), 
136.32 [C-o, 2J (13C-119Sn) = 55 Hz], 139.36 (C-i), 139.78 (C-2), 140.70 (C-4), 
163.02 (C-7), 165.02 (C-1), 168.92 (C-8). COSY correlation [δH/δH]: 7.03/7.56 
(H-5/H-3), 7.40/7.86 (H-m, H-p/ H-o), 7.47/8.21 (H-11, H-12,H-13/ H-10,H-14). 
HETCOR correlation [δH/δC]: 7.03/129.05 (H-5/C-5), 7.40/128.91 (H-m/C-m), 
7.40/130.49 (H-p/C-p), 7.47/128.38 (H-11,H-13/C-11,H-13), 7.47/131.23 (H-
12/C-12), 7.56/131.13 (H-3/C-3), 7.86/136.34 (H-o/C-o), 8.21/127.84 (H-10,H-
14/C-10,H-14). 119Sn NMR (149 MHz, CDCl3, ppm, 298 K) δ: - 324.40. IR-ATR 
νmax cm-1: 3090, 2990, 1600 (C=N), 1400, 1200, 790. UV/Vis: λmax (nm) = 
428 (CHCl3, 1x10-3 M). TOF calc. for [(C34H37N2O2Sn+H)+] : 625.187154; 
Found: 625.187862 (error = 0.759457 ppm). 
 
4.2.1.3 [N-(1-oxide-10-naphthaldehyde)-benzyhydrazidato] di-n-
butyltin(IV).(3) 
  
A solution of  2-
hydroxynaphthaldehyde (0.17g, 1mmol), 
benzoic hydrazide (0.13g, 1mmol), and di-
n-butyltin oxide (0.25g, 1mmol) in benzene 
(50 ml) was heated to reflux for 24 hr in a 
Dean-Stark apparatus used for the 
azeotropic removal of water and allowed to cool to room temperature. Then, all 
volatiles were removed under vacuum. Yield: 85%. Brown oil.1H NMR (400.13 
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MHz, CDCl3, 298 K) δ: 0.74 (t, 6H, 3J = 8 Hz, CH3-δ), 1.25 (m, 4H, CH2-γ), 1.43 
(t, 4H, 3J = 8 Hz, CH2-α), 1.56 (m, 4H, 3J = 8 Hz, CH2-β), 6.84 (d, 1H, 3J = 8 Hz, 
H-2), 7.15 (t, 1H, 3J = 8 Hz, H-6),  7.33, (m, 3H, H-15-17), 7.37 (t, 1H, 3J = 8 Hz, 
H-7), 7.53 (d, 1H, 3J = 8 Hz, H-5), 7.61 (d, 1H, 3J = 8 Hz, H-3), 7.94 (d, 1H, 3J = 
8 Hz, H-8), 8.03 (m, 2H, H-14, H-18), 9.60 (s, 1H, 3J (1H-119Sn) = 48 Hz, H-11). 
13C NMR (100.61 MHz, CDCl3, 298 K) δ: 13.69 (Cδ), 22.06 [Cα, 1J (13C-
119/117Sn) = 595/576 Hz], 26.54 [Cγ, 3J (13C-119Sn) = 82 Hz], 26.96 [Cβ, 2J (13C-
119Sn) = 35 Hz], 107.17 (C-9), 119.21 (C-8), 123.05 (C-6), 124.46 (C-2), 127.25 
(C-4), 127.64 (C-14,18), 128.08 (C-7), 128.33 (C-15,17), 129.23 (C-5), 130.88 
(C-16), 133.74 (C-10), 133.93 (C-13), 136. 61 (C-3), 156.97 [C-11, 2J (13C-119Sn) 
= 20 Hz], 168.55 [C-12, 2J (13C-119Sn) = 10 Hz], 169.42 [C-1, 2J (13C-119Sn) = 33 
Hz]. COSY correlation [δH/δH]: 0.74/1.25 (H-δ/H-γ), 1.56/1.25 (H-β/H-γ), 
1.56/1.43 (H-β/H-α), 6.84/7.60 (H-2/H-3), 7.15/7.36 (H-6/H-7), 7.15/7.53 (H-6/H-
5), 7.33/8.03 (H-15/H-14). HETCOR correlation [δH/δC]: 0.74/13.69 (H-δ/C-δ), 
1.25/26.54 (H-γ/C-γ), 1.43/22.06 (H-α/C-α), 1.59/26.96 (H-β/C-β), 6.84/124.45 
(H-2/C-2), 7.15/123.05 (H-6/C-6), 7.33/128.33 (H-15, H-17/C-15, C-17), 
7.33/130.88 (H-16/C16),  7.36/128.08 (H-7/C-7), 7.53/129.23 (H-5/C-5), 
7.60/136.61 (H-3/C-3), 7.94/119.21 (H-8/C-8), 8.03/127.64 (H-14, H-18/C-14, C-
18), 9.60/156.97 (H-11/C-11). 119Sn NMR (149 MHz, CDCl3, ppm, 298 K) δ: - 
189.99. IR-ATR νmax cm-1: 3090, 2980, 1600 (C=N), 1410, 1200, 760. UV/Vis: 
λmax (nm) = 441 (CHCl3, 1x10-3 M). TOF calc. for [(C26H31N2O2Sn+H)+] : 
523.140203; Found: 523.140324 (error = 0.229467 ppm). 
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4.2.1.4 [N-(1-oxide-10-naphthaldehyde)-benzyhydrazidato] 
diphenyltin(IV).(4) 
 	  A solution of  2-
hydroxynaphthaldehyde (0.17g, 1mmol), 
benzoic hydrazide (0.13g, 1mmol), and di-
phenyltin oxide (0.29g, 1mmol) in benzene 
(50 ml) was heated to reflux for 24 hr in a 
Dean-Stark apparatus used for the 
azeotropic removal of water and allowed to 
cool to room temperature. Then, all volatiles were removed under vacuum. 
Yield: 80%. Yellow solid. MP:200ºC. 1H NMR (400.13 MHz, DMSO-d6, 298 K) δ: 
7.19 (d, 1H, 3J = 8 Hz, H-2), 7.30-7.39 (m, 7H, H-6, H-m, H-p), 7.50-7.55 (m, 4H, 
H-7,H-15, H-16, H-17), 7.70 (d, 4H, 3J = 8 Hz, H-o),  7.81 (d, 1H, 3J = 8 Hz, H-
5), 7.93 (d, 1H, 3J = 8 Hz, H-3), 8.19 (d, 2H, 3J = 8 Hz, H-14, H-18), 8.26 (d, 1H, 
3J = 8 Hz, H-8), 9.62 (s, 1H, 3J (1H-119Sn) = 52 Hz, H-11). 13C NMR  (100.61 
MHz, DMSO-d6, 298 K) δ: 107.51 (C-9), 119.97 (C-8), 123.01 (C-6), 124.48 (C-
2), 126.85 (C-4), 127.27 (C-14,18), 128.02 (C-7), 128.40 (C-15,17), 128.47 (C-
p), 128.91 (C-5), 129.24 (C-m), 131.09 (C-16), 133.28 (C-10), 133.42 (C-13), 
134.88 [C-o, 2J (13C-119Sn) = 55 Hz], 135.99 (C-3), 154.16 (C-i) , 158.46 (C-11), 
166.60 (C-12), 167.92 (C-1). COSY correlation [δH/δH]: 7.19/7.94 (H-2/H-3), 
7.30-7.39/7.56 (H-m,H-p/H-o), 7.30-7.39/7.81 (H-6/H-5), 7.30-7.39/7.50-7.55 (H-
6/H-7), 7.50-7.55/8.26 (H-7/H-8), 7.50-7.55/8.19 (H-15, H-17/ H-14, H-18). 119Sn 
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NMR (149 MHz, DMSO-d6, 298 K) δ: - 406.72 ppm. IR-ATR ṽmax cm-1: 3090, 
1610 (C=N), 1200, 790. UV/Vis: λmax (nm) = 437 (CHCl3, 1x10-3 M). Anal. 
calcd. for C30H22N2O2Sn: C 64.20 %, H 3.95 %, N 4.99 %; Found: C 64.14 %, H 
4.10 %, N 4.72 %.  
 
4.2.2 Bioassays 
 
4.2.2.1 Cell culture. 
 
B16F10 cell line was cultured in 25 cm2 flasks, DMEM / F12 was used as 
culture medium supplemented with 5% fetal bovine serum (FBS). Cell passage 
was performed twice a week and the culture was maintained at 37 ° C in an 
atmosphere of 5% CO2 and 95% humidity. 
 
For the manipulation of cells and culture medium the trypsin was heated at 
37º C. When the culture plates reach a confluence of 80% or more, is necessary 
to pass the cells to have enough cells to work. 
 
For the first pass of cells, the culture medium was removed from the bottle 
and subsequently 1 ml trypsin was added, ensuring that the trypsin completely 
covers the floor of the plate, after 5 minutes, when the cells are detached, the 
trypsin was inactivated with 3 ml of culture medium and carefully shaken with a 
pipette several times to make sure there are no clumps of cells in the culture. 
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8 ml of medium was added in an empty flask properly labeled and 
subsequently added 3-5 drops of cell culture (depending on the junction) and 
stirred gently before narrow plate, and allowed to incubate at 37ºC. The 
remaining cell culture is counting, for your later use in the bioassays. 
 
4.2.2.2 Cytotoxicity. 
 
Part A 
 
The neutral red assay system is a way of measuring living cells via the 
uptake of the vital dye neutral red (Figure 6). Viable cells will take up the dye by 
active transport and incorporate the dye into lysosomes, whereas non-viable 
cells will not take up the dye. After the cells have been allowed to incorporate 
the dye they are briefly washed or fixed. The incorporated dye is then liberated 
from the cells in an acidified ethanol solution. An increase or decrease in the 
number of cells or their physiological state results in a concomitant change in 
the amount of dye incorporated by the cells in the culture. This indicates the 
degree of cytotoxicity caused by the test material. xxviii  
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Figure 6. Molecular structure of Neutral red. 
 
HGF1 (gingival biopsy) and A-375 (melanoma cells) cells were seeded in 96 
wells plates at a density of 1x104 per well in 100 ml of media and incubated for 
24 hours at 37°C. Media was exchanged and compounds were added at 
concentrations ranging from 3 µg/ml to 50 µg/ml. Twenty four hours later, media 
was removed, and 100 µl of  Neutral Red (Sigma-Aldrich) were added to each 
well, and after 2 hours of incubation, the medium was carefully removed and the 
cells quickly rinsed with PBS, and a fade solution was added. Viability of the 
cultures was measured by spectrophotometry on an ELISA Microplate Reader 
(Biotek Multiskan ELX800, BioTek Instruments, Inc, Winooski, VT) at 
wavelength of 540 nm.The data obtained were then analyzed by computer. 
 
Part B 
 
The cell viability assay Alamar Blue is widely used for measurement of 
proliferation and cytotoxicity in several cell lines (human, animals, fungi and of 
bacteria strains) xxix  , xxx  , xxxi  This nontoxic and highly permeable membrane 
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reactive, uses the advantage of the reducing environment within healthy cells to 
reduce resarzurine (blue reagent) to resorufin (red reactive). (Scheme 4) The 
color change is directly proportional to the number of living cells. Can thus relate 
the change in the color of the cell culture with the viability and cytotoxicity. 
 
 
 
Scheme 4. Reduction of Alamar blue reagent within metabolically active cells. 
 
B16F10 murine melanoma cells were seeded in 96 wells plates at a 
density of 1x104 per well in 100 ml of media and incubated for 24 hours at 37°C. 
Media was exchanged and compounds were added at concentrations ranging 
from 0.01 µg/ml to 10 µg/ml. Untreated cells or treated with dimethyl sulfoxide 
(DMSO, Sigma-Aldrich Co, St. Louis, MO) were used as controls. Twenty four 
hours later 10 µl of alamarBlue (Biosource Invitrogen Life Technologies, 
Carlsbad, CA) were added to each well. Viability of the cultures was measured 
as reagent colour change by spectrophotometry on an ELISA Microplate Reader 
(Biotek Multiskan ELX800, BioTek Instruments, Inc, Winooski, VT) at dual 
wavelength of 570 and 600 nm. The data obtained were then analyzed by 
computer. 
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4.2.2.3 Cell images. 
 
B16F10 murine melanoma cells were seeded in 6 wells plates on sterile 
coverslips at a density of 2x105 cells/well in 2 ml of DMEM/F12 media and 
maintained at 37°C in a controlled humid atmosphere of 5% CO2 and 95% air. 
24 hours later media was exchanged and cells were exposed to the compounds 
at concentration of 10 µg/ml, for two hours. Untreated cells or treated with 
DMSO were used as controls. Supernatants were removed and coverslips were 
washed once with 2 ml of PBS, mounted on microscope slips using glycerol 
75% and imaged using confocal laser microscopy (Leica TCS SP5 Confocal 
System). Samples were excited at 405 and 458 nm and the fluorescence 
emission was measured at 478-612 nm. 
 
Compounds that showed good cell staining were selected. And stains at 
lower concentrations of 1 µg/ml and 0.1 µg/ml were performed. Each experiment 
was performed in duplicate and repeated 3 times. 
 
Each compound was excited to a specific wavelength and reading the 
emission wavelengths according to the absorption and emission values of each 
compound used was performed. (Table 2) 
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TABLE 2 
Parameters used with each compound. 
 
Compound Excitaton (nm) Emission (nm) 
1 458 478-612 
2 458 475-550 
3 405 420-500 
4 458 475-550 
 
 
4.3 Disposal of hazardous waste. 
 
The organic waste generated in the reactions like benzene, as well as for the 
work up: hexane, acetone, ethyl acetate were collected in the container C, which 
is assigned for halogen free-solvents. Waste of solvents like chloroform and 
dichloromethane were collected in container D, which is assigned for halogen 
containing solvents. Biological waste was disposed in the appropriate 
containers. 
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5. RESULTS AND DISCUSSION 
 
5.1 Synthesis. 
 
We carry out the synthesis of Schiff bases 1-4 (Figure 7) by condensation 
reaction of the appropriate salicylaldehyde or napthaldehyde with the 
corresponding benzohydrazides in benzene for 48 hours. The Schiff bases were 
isolated with good yields (75-85%). 
 
 
 
Figure 7. Schiff bases 1-4 
 
The products were obtained after filtration of the crude reaction and 
precipitation using hexane, as yellow powders and one of the compounds as 
brown oil, where all compounds were soluble in common organic solvents such 
as dichloromethane, chloroform and acetone. 
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5.2 Chemical structure elucidation. 
 
Organotin complexes were characterized by UV-vis, spectroscopic 
methods (IR, 1 and 2D-NMR), mass spectrometry and powder X-ray single 
crystal. 
 
5.2.1 UV Analysis 
 
The UV-Vis spectra of the compounds and its ligands were obtained in 
chloroform (Figure 8). As we can see, the free ligands present a main 
absorption peak in the UV region (260-390 nm), but after the coordinated bond 
is formed N è Sn, the bands are red-shifted (400-450 nm) due to the larger 
electronic delocalization.  	  
	  
Figure 8. Absorption spectrum of compounds 1-4 (left) and its ligands (right), in 
chloroform. 
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The emission spectrum, showed wavelengths for compounds 1-4 between 468 
to 513 nm (Figure 9), being compounds 3 and 4 the most red-shifted, attributed 
to the presence of naphthalene group. The data are represented in Table 3. 
 
 
 
Figure 9. Emission spectra of compounds 1-4 in chloroform. 
 
TABLE 3 
Absorption and emission data of compounds 1-4 
 
Compound Max. Absorption 
(nm) 
Emission 
(nm) 
1 402 468 
2 428 505 
3 441 513 
4 437 509 
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5.2.2 Analysis of NMR data 
 
NMR spectroscopy is a reliable and powerful tool to obtain information 
about the structure, 1H, 13C and 119Sn NMR analyses, collectively provide highly 
valuable information and hence are used for the characterization of organotin 
compounds. 
 
1H-NMR spectra confirmed the formation of the Schiff bases 1-4 (see 
appendix), with signals for H-7 (compounds 1 and 2) and H-11 (compounds 3 
and 4) in the range 8.67 to 9.62 ppm, typical of an imine proton, which are 
according to reported by Santillan et al. xxxii  
 
 In the same manner it is possible to see satellite signals for this protons 
(nJ1H-119Sn: 48-56 Hz) due coupling with 119Sn, which are according to reported 
by Smith for organotin compounds. xxxiii  In addition to the signals of the aromatic 
rings of the molecule, it is also possible to notice the signals for the substituents. 
For compounds 1 and 2 the coupling of the ortho protons due to the proximity of 
tin is appreciated. (Table 4). 
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TABLE 4 
1H-NMR data of Sn substituents (ppm). 
 
Comp. CH2-α CH2-β/CHo CH2-γ /CHm CH3-δ /CHp 
1  7.89 [84/72] 7.42 7.42 
2  7.86 [84/68] 7.40 7.40 
3 1.43 1.56 1.25 0.74 
4  7.56 7.35 7.35 
 
 
In the 13C NMR spectra of tin compounds, the principal signals correspond 
to C-11/C-7 (C=N) between 156.97 to 163.02 ppm, C-1 (C-O) with shifts 
between 165.02 to 169.87 ppm and C-12/C-8 (N=C-O) that appear between 
166.60 to 168.92 ppm.  
 
The existence of the N è Sn coordination bond was evidenced by 119Sn-
NMR spectra for the compounds 1-4, observed values for the chemical shifts 
confirm that the compounds are pentacoordinated. Five- and six-coordinate 
organotin compounds show 119Sn signals, which occur at much lower 
frequencies than those of the four-coordinate derivatives. Has been reported 
that signals between -204 to -395 ppm are indicative of pentacoordinated tin 
atoms, which is consistent with the chemical shifts obtained. (Table 5)  
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TABLE 5 
Selected 1H (nJ1H-119Sn), 13C [nJ13C-119Sn], and 119Sn (ppm). 
 
Comp. 1H 
H-11/H-7 
13C 
C-11/C-7    C-α/Ci       C-1        C-12/C-8 
119Sn 
 
1 8.67 
(54) 
161.04 
 
139.46 
 
169.87 168.26 -330.31 
2 8.83 
(56) 
163.02 139.36 165.02 168.92 -324.40 
3 9.60 
(48) 
156.97 
[20] 
22.06 
[595/576] 
169.42 
[34] 
168.55 
[10] 
-189.90 
4 9.62 
(52) 
158.46 154.16 167.92 166.60 -406.73 
 
 
5.2.3 Analysis of IR data 
 
The IR spectral analysis showed that the C=N stretching vibration bands 
for compounds 1-4 (1600-1610 cm-1) were shifted to lower wavenumbers in 
comparison with the ligands (1635 cm-1), demonstrating a decrease in strength 
as the new dative bond is formed. Main bands are shown in Table 6: 
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TABLE 6 
 Main IR bands of the four compounds. 
 
 1 2 3 4 
C-H arom. 3090 cm-1 3090 cm-1 3090 cm-1 3090 cm-1 
C-H sp3 stre. 2990 cm-1 2990 cm-1 2980 cm-1 - 
C=N 1600 cm-1 1600 cm-1 1600 cm-1 1610 cm-1 
C-H sp3 bend. 1400 cm-1 1400 cm-1 1400 cm-1 - 
C-H arom. IP 1200 cm-1 1200 cm-1 1200 cm-1 1200 cm-1 
C-H arom. OP 770 cm-1 790 cm-1 760 cm-1 790 cm-1 
 
  
 
5.2.4 Mass spectra. Molecular ion and fragmentation. 
 
The mass spectra of the four molecules, was obtained by the TOF method. 
The spectra of organotin compounds 1 and 2 showed that the base peak 
correspond to the molecular ion peak (Scheme 5), while compounds 3 and 4 
showed a base peak after loss of the di-n-butyltin and di- phenyltin fragment 
(Scheme 6). 
The presence of the base peak of the tin compounds is consistent with the 
theoretical molecular mass. 
 
 
	  	   39	  
 
 
Scheme 5. Proposed fragmentation of tin compounds (1 and 2). 
 
 
 
Scheme 6. Proposed fragmentation of tin compounds (3 and 4). 
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5.2.5 Elemental analysis. 
  
The elemental analysis data of the compound 4 (C30H22N2O2Sn) is given in 
Table 7. The results obtained for C, H and N are in good agreement with those 
calculated for the suggested formula, indicating the purity of the tin compound. 
 
TABLE 7 
 Elemental analysis of compound 4 (C30H22N2O2Sn). 
 
Element Calc. (%) Found (%) 
C 64.20 64.14 
H 3.95 4.10 
N 4.99 4.72 
 
 
5.2.6 X-ray analysis 
 
The structures of compounds 1,2 and 4 are represented by the thermal 
ellipsoid plots in figures 10, 11 and 12. Selected bond distances and angles are 
listed in Table 9 and 10. Compounds 1 and 2 belongs to triclinic space group P-
1 and compound 4 to monoclinic space group P21/c (Table 8). 
 
The crystal structures of the compounds, (Figures 8, 9 and 10) shows that 
the molecules contain a pentacoordinated tin atom, and the formation of five-
ring-fused skeletons whit N è Sn coordination bond with lengths of 2.143 Ǻ, 
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2.137 Ǻ and 2.147 Ǻ respectively, characteristic of this type of bonds. The C-C 
bond lengths of the aromatic systems correspond to the data previously reported 
for similar molecules.xxxiv   
 
 
 
 
 
Figure 10. X-ray molecular structure of compound 1. 
 
 
 
 
Figure 11. X-ray molecular structure of compound 2. 
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Figure 12. X-ray molecular structure of compound 4. 
 
 
As we can see in every molecule, the tin atom adopts a distorted trigonal 
bipyramid geometry, where the apical position is occupied by oxygen atoms (Sn-
O1 2.080(2) Å and Sn-O2 2.123(2) Å compound 1, Sn-O1 2.082(1) Å and Sn-O2 
2.138(1) Å compound 2, Sn-O1 2.0773(13) Å and Sn-O2 2.1203(13) Å 
compound 4) and the equatorial by nitrogen and the ipso-carbons (Sn-C16 
2.123(3) Å and Sn-C22 2.126(2) Å compound 1, Sn-C23 2.120(2) Å and Sn-C29 
2.111(2) Å compound 2, Sn-C19 2.1101(19) Å and Sn-C25 2.1164(18) Å 
compound 4). 
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In the three compounds, the bond angle O-Sn-O is in the interval of 
156.90º (7) to 158.23º (5), far from the ideal angle (O-Sn-O 180º) due to the 
tension generated by the formation of 5-membered plane rings. 
 
Another important aspect observed by X-ray analysis is the intermolecular 
interactions; pi interactions and hydrogen bonds are the principals, as we can 
see in figures 13, 14 and 15,  
 
 
 
 
Figure 13. Intermolecular interactions of compound 1. 
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Figure 14. Intermolecular interactions of compound 2. 
 
 
Figure 15. Intermolecular interactions of compound 4. 
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TABLE 8 
Crystal data for compounds 1, 2 and 4. 
 1 2 4 
Empirical 
formula 
C27H22N2O3Sn C34H36N2O2Sn C30H22N2O2Sn 
Formula weight 541.15 623.34 561.19 
Temperature, K 293(2) 100(2)  100(2)  
Wavelength 0.71073 0.71073 0.71073 
Cryst size, mm3 0.15x0.07x0.05 0.15x0.05x0.04 0.12x0.11x0.10 
Crystal system Triclinic Triclinic Monoclinic 
Space group P-1 P-1 P21/c 
a, Å 8.7687(2) 10.3043(12) 9.8450(12) 
b, Å 11.4801(2) 11.1764(13) 8.6454(10) 
c, Å 13.2600(2) 12.8993(15) 28.744(3) 
α 64.2670(10) o 85.3470(10) o 90 o 
β 81.3370(10) o 87.3890(10) o 93.0780(10) o 
γ  90.3440(10)o 83.9970(10) o 90 o 
V,Ǻ3 1184.90(4) 1471.5(3) 2443.0(5) 
Z 2 2 4 
ρcalc,Mg.cm-3 1.517 1.407 1.526 
µ , mm-1 1.109 0.901 1.076 
2θ  range for 
data collection 
1 – 14 ° 2.33 – 28.33 ° 1.42 – 28.3 ° 
Index ranges -10 ≤ h ≤ 11,  
-14 ≤ k ≤ 14, 
 -17 ≤ l ≤ 17 
-13 ≤ h ≤ 13,  
-14 ≤ k ≤ 14, 
 -16 ≤ l ≤ 16 
-13 ≤ h ≤ 13,  
-11 ≤ k ≤ 11,  
-38 ≤ l ≤ 38 
No. reflns 
collected 
26003 14585 23387 
No. indep reflns 4712 6954 6086 
[Rint] 0.0268 0.0282  0.0266  
Goodness of fit 1.062 1.081 1.065 
R1, wR2 (I>2σ(I)) 0.0345  
0.0662 
0.0293 
0.0727  
0.0287 
0.0730  
R1, wR2 (all 
data) 
0.0268 
0.0627 
0.0282  
0.0718  
0.0310 
0.0748 
Δρmin (e Ǻ-3) - 0.602 - 0.653 - 0.656 
Δρmax (e Ǻ-3) 0.528 1.140 1.552 
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TABLE 9 
Selected bond distances (Å) for 1, 2 and 4. 
 
 1 2  4 
Sn-O(1) 2.080(2) 2.082(1) Sn-O(1) 2.0773(13) 
Sn-O(2) 2.123(2) 2.138(1) Sn-O(2) 2.1203(13) 
Sn-N(1) 2.143(2) 2.137(1) Sn-N(1) 2.1478(15) 
Sn-C(16) 2.123(3)  Sn-C(19) 2.1101(19) 
Sn-C(22) 2.126(2)  Sn-C(25) 2.1164(18) 
Sn-C(23)  2.120(2) C(1)-O(1) 1.305(2) 
Sn-C(29)  2.111(2) C(10)-C(11) 1.426(3) 
C(1)-O(1) 1.326(2) 1.330(2) C(11)-N(1) 1.303(2) 
C(8)-O(2) 1.311(3) 1.306(2) N(1)-N(2) 1.403(2) 
C(6)-C(7) 1.420(4) 1.435(2) N(2)-C(12) 1.309(2) 
C(7)-N(1) 1.299(2) 1.303(2) C(12)-O(2) 1.305(2) 
N(1)-N(2) 1.397(3) 1.398(2)   
N(2)-C(8) 1.304(2) 1.311(2)   
C(15)-O(3) 1.413(5)    
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TABLE 10 
Selected angles (o) for 1, 2 and 4. 
 
 1  2  4 
C(16)-Sn-C(22) 125.28(9) C(23)-Sn-C(29) 129.95(7) C(19)-Sn-C(25) 120.13(7) 
C(16)-Sn-N(1) 108.06(8) C(23)-Sn-N(1) 117.60(6) C(19)-Sn-N(1) 123.30(6) 
C(16)-Sn-O(1) 96.31(8) C(23)-Sn-O(1) 94.43(6) C(19)-Sn-O(1) 96.80(6) 
C(16)-Sn-O(2) 98.08(8) C(23)-Sn-O(2) 92.64(6) C(19)-Sn-O(2) 94.06(6) 
C(22)-Sn-N(1) 126.48(8) C(29)-Sn-N(1) 112.11(6) C(25)-Sn-N(1) 116.30(6) 
C(22)-Sn-O(1) 93.11(8) C(29)-Sn-O(1) 95.78(6) C(25)-Sn-O(1) 95.43(6) 
C(22)-Sn-O(2) 93.21(8) C(29)-Sn-O(2) 95.38(6) C(25)-Sn-O(2) 96.50(6) 
O(1)-Sn-O(2) 156.90(7) O(1)-Sn-O(2) 158.23(5) O(1)-Sn-O(2) 157.04(5) 
N(1)-Sn-O(1) 84.56(7) N(1)-Sn-O(1) 74.17(5) N(1)-Sn-O(1) 74.23(5) 
N(1)-Sn-O(2) 73.85(7) N(1)-Sn-O(2) 84.32(5) N(1)-Sn-O(2) 82.90(5) 
 
 
5.3 Bioassays 
 
5.3.1 Cytotoxic selectivity 
 
Organotin compounds were used on two different cell lines in order to 
compare the behavior in normal and cancer cells. HGF1 (gingival biopsy) and A-
375 (melanoma cells) human cells were treated with five different concentrations 
of the compounds (50, 25, 12, 6, and 3 µg/ml) for 24 hours and then viability 
was determined using Neutral Red Technique (Figure 16 and 17).  
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As we can appreciate, the compounds at different concentrations, follow 
the same tendency in both of the cell lines, this behavior indicate that there is no 
selectivity for melanoma cancer cells with none of the compounds. Studies with 
other cell lines are required to evaluate the selectivity for other cancer cells. 
These results cannot indicate the real cytotoxicity of the compounds, because 
the experiment was performed only once by duplicated, more number of 
experiments are required to perform in order to determinate the cytotoxic effect 
of each compound. 
 
	  	  
Figure 16.Cytotoxic effect of organotin compounds. Gingival cells HGF1 were 
treated with 50 µg/ml (blue bars), 25 µg/ml (red bars), 12 µg/ml (green bars), 6 
µg/ml (purple bars), 3 µg/ml (light blue bars), for 24 hours. Untreated cells were 
used as controls. (Data represents media +/- SD of the duplicated of one 
experiment). 
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Figure 17.Cytotoxic effect of organotin compounds. Melanoma cells A-375 were 
treated with 50 µg/ml (blue bars), 25 µg/ml (red bars), 12 µg/ml (green bars), 6 
µg/ml (purple bars), 3 µg/ml (light blue bars), for 24 hours. Untreated cells were 
used as controls. (Data represents media +/- SD of the duplicated of one 
experiment). 
 
5.3.2 Cytotoxic capacity evaluation 
 
Organotin compound, were used on tissue culture in order to assess their 
cytotoxic effects. B16F10 murine melanoma cells were treated with three 
different concentrations of the compounds (10, 5, and 2.5 µg/ml) for 24 hours 
and then viability was determined by Alamar Blue. As DMSO was the solvent 
used for the compounds, its toxicity was analyzed as well (Figure 18). The 
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viability of the cells was greatly affected by the higher concentrations tested, 
being compounds 1 y 4 the more toxic (showing 0% of viability a concentration 
of 10 µg/ml), and also compound 3 presents considerable toxicity, while 
compound 2 did not present toxic activity. When lower concentrations of 
compounds were used, a dose-response effect tendency was observed for all 
compounds, except for compound 2 which remained non-toxic at all tested 
concentrations.  
 
 
 
 
 
Figure 18. Cytotoxic effect of organotin compounds. Murine melanoma cells 
B16F10 were treated with 10 µg/ml (blue bars), 5 µg/ml (red bars), 2.5 µg/ml 
(green bars) for 24 hours. As controls, cells treated with DMSO and untreated 
cells were used. (Data represents media +/- SD of three independent 
experiments). Significant difference from the DMSO control is represented by an 
asterisk (P < 0.05). 
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In order to corroborate that the toxic effects are due to the organotin 
compounds and not to their metabolites, the same cytotoxic assay was 
performed with the ligands of each compound. B16F10 cells were treated with 
three different concentrations of the ligands (10, 5, and 2.5 µg/ml) for 24 hours 
and then viability was determined (L-1: ligand of compound 1, L-2: ligand of 
compound 2, L-3&4: ligand of compound 3 and 4) . As we can see (Figure 19), 
none of the ligands presents significant cytotoxic effect with the different 
concentrations, which suggest that the ligand has no influence on the 
cytotoxicity. While the organotin moiety is crucial for cytotoxicity, the ligand 
design also plays a key role in transporting and addressing the molecule to the 
target. xxi 
 
 
 
Figure 19. Cytotoxic effect of organotin compounds and its ligands. Melanoma 
cells B16F10 were treated with 10 µg/ml (blue bars), 5 µg/ml (red bars), 2.5 
0	  
20	  
40	  
60	  
80	  
100	  
120	  
UT	   DMSO	   1	   2	   3	   4	   L-­‐1	   L-­‐2	   L-­‐3&4	  
%
 V
iab
ilit
y	

Compounds	

Concentrations	
10μg	  /ml	   5μg	  /ml	   2.5μg	  /ml	  
*	  	  	  	  *	  
	  *	  	  
	  	  	  	  *	  	  	  	  	  
	  	  	  *	   	  *	  
	  	  *	  	  	  *	  	  	  *	  
	  	   52	  
µg/ml (green bars) of each compound for 24 hours. Cells treated with DMSO 
and untreated cells were used as controls. (Data represents media +/- SD of 
three independent experiments). Significant difference from the DMSO control is 
represented by an asterisk (P < 0.05). 
 
As compounds, 1, 3 and 4 showed the best cytotoxic effect, we determined 
their toxicity effects at lower concentrations (1 µg/ml and 0.1 µg/ml) (Figure 20). 
A dose-response effect tendency was observed for compounds1 and 4, both 
compounds at 0.1 µg/ml are practically innocuous to cells. As we can see, 
compound 3 is very cytotoxic at concentration of 10 µg /ml, and a concentration 
of 5 µg /ml and lower showed not significant change. 
 
 
 
Figure 20. Cytotoxic effect of organotin compounds. Melanoma cells B16F10 
were treated with 10 µg/ml (blue bars), 5 µg/ml (red bars), 2.5 µg/ml (green 
bars), 1 µg/ml (purple bars) and 0.1 µg/ml (light blue bars) of each compound for 
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24 hours. Cells treated with DMSO and untreated cells were used as controls. 
(Data represents media +/- SD of three independent experiments). Significant 
difference from the DMSO control is represented by an asterisk (P < 0.05). 
 
Silva et. al, xxxv  reported the Inhibitory concentration of 50% (IC50) of cell growth 
using the cell line B16F10 for cisplatin and carboplatin, 4.2 and 6.3 µmol/L 
respectively, this values converted to µg/ml are represented in Table 11: 
 
TABLE 11 
Inhibitory concentration of 50% of cell growth for cisplatin and carboplatin. 
 
 B16F10 
Cisplatin 1.26 µg/ml 
Carboplatin 2.33 µg/ml 
 
Compound 1 at concentration of 2.5 and 1 µg/ml maintains similar 
cytotoxicity under 50% of cell growth, this result is favorable if we compare with 
the IC50 from the cisplatin, with concentration of 1 µg/ml we can observe almost 
the same toxicity that cisplatin has at 1.26 µg/ml, and it is almost the half 
amount that carboplatin needs to inhibit the 50% of cell growth. 
 
Compound 3 only has good cytotoxicity at high concentration of 10 µg/ml, 
at concentrations of 5, 2.5, 1 and 0.1 maintains the same behavior with viability 
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up to 50%, if we compare with cisplatin and carboplatin, this compound is not a 
good cytotoxic agent, because it requires a lot of concentration to observe a 
toxic effect. 
 
Finally, compound 4 has a very good toxic capacity at concentration of 5 
and 2.5 µg/ml, with less than 20% of viability, but at lower concentration of 1 
µg/ml the viability increments almost to 70%. This means that the IC50 of this 
compound is between 2.5 and 1 µg/ml. And the value will be similar to those 
reported for cisplatin and carboplatin (1.26 and 2.33 µg/ml respectively), 
considering this compound like a good cytotoxic agent for this cell line. 
 
5.3.3 Bioimages 
 
To evaluate the behavior of the luminescent organotin compounds in cells, 
confocal fluorescence microscopy measurement was carried out. Briefly, 
melanoma cells B16F10 were seeded at 2 x 105 cells/2 ml media per well in 6 
wells plates on sterile coverslips, 24 h later media was removed and fresh media 
and the compounds at 10 µg/ml were added. Two hours later media and 
compounds were removed and cells were washed once with PBS. Coverslips 
were recovered and mounted on microscope slides using 75% glycerol. Cells 
were analyzed by confocal microscopy in a Leica SP5 system using a 458 nm 
laser to excite the luminescence while emission was registered between 478 
and 612 nm. These experiments were performed three times in duplicate. 
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Figure 21. Staining of cells with organotin compounds. Confocal 
microscopy of melanoma cells B16F10 treated with 10 µg/ml of each compound 
for 2 h. A, Untreated cells; D, DMSO control; B, Compound 1; C, Compound 2; 
E, Compound 3; F, Compound 4. (Scale bar shown represents 7.5 µm).  
 
 
Cells exposed to each organotin compound at 10 µg/ml showed different 
staining patterns ranging from lack of stain to very strong staining (Figure 21). 
 
Treatment of cells with compound 2 did not produce staining (Figure 21-
C). Compound 1 produces a good staining, but it quickly presents 
photobleaching and its fluorescence disappear after a few seconds (Figure 21-
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B). Cells exposed to compound 3 showed a strong green cytoplasmic staining 
with focalized vesicle-like structures showing stronger staining (Figure 21-E). 
Compound 4 produced the stronger effect with yellow cytoplasmic staining 
showing as well brighter focalized vesicle-like structures (Figure 21-F). It is 
important to notice that neither compound is able to stain the nucleus. 
 
The three compounds that present cell staining are the most cytotoxic, 
unlike the compound 2 which does not exhibit luminescence nor cytotoxicity, 
proving that its no toxicity is caused by the inability of the compound to 
penetrate the cell, probably because the molecule has tert-butyl groups which 
make this section largest, which prevents the passage into the cell. 
 
The staining capacity of the ligands was analyzed as well at the highest 
concentration (10 µg/ml), but none of the three ligands produced cell staining. 
Images with the ligands of the compounds 2, 3 and 4 presented the same 
pattern of extracellular crystals formation with intense fluorescence, but no one 
was capable of penetrate the cell. Crystal formation suggests precipitation of the 
ligands due the low solubility, reaffirming that Sn may increase the solubility of 
the compounds. 
 
5.3.3.1 Dose-response study. 
 
We analyzed the capacity of compounds 3 and 4 to stain the cells at lower 
concentrations due its good staining capacity (Compound 1 was not used due to 
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the photobleaching showed). Similar to the previous experiments, B16F10 cells 
were treated now with 1 µg/ml or 0.1 µg/ml of each compound for two hours and 
then analyzed by confocal microscopy. As shown in Figure 22, compound 3 is 
able to produce both cytoplasmic and focalized green staining even when we 
lower two magnitude orders its concentration (Figure 22 B-D). At 1 µg/ml 
produced a staining pattern similar to that at the higher concentration and the 
brighter vesicle-like structures are still visible (Figure 22-C), however at the 
lower concentration of 0.1 µg/ml, the cytoplasmic staining is almost undetectable 
(Figure 22-D). On the other hand, lowering the concentration of compound 4 
resulted in a very weak staining at 1 µg/ml and a complete lack of staining at 0.1 
µg/ml (Figure 22-G and 22-H, respectively). 
 
	  
Figure 22. Staining of cells with organotin compounds 3 and 4. Confocal 
microscopy of melanoma cells B16F10 treated with compound 3 (B-D) or 
compound 4 (F-H) at three different concentrations: 10 µg/ml (B and F), 1 µg/ml 
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(C and G), or 0.1 µg/ml (D and H) of each compound for 2 h. A, Untreated cells; 
E, DMSO control. (Scale bar shown represents 20 µm). 
 
The very strong cytoplasmic staining in the cells with numerous vesicle-like 
structures showing a stronger staining, suggests that the possible internalization 
mechanism of the organotin compounds is endocytosis. We hypothesize that 
after endosome processing the compound and/or its metabolites are released to 
the cytosol. Once in the cytoplasm they are not able to get into the nucleus. 
Vesicle formation may be influenced by the solubility of the molecule, if not 
completely solubilized microprecipitates are formed which lead to the 
internalization of the compound by endosomes.  
 
Another possible mechanism is that the compounds are being recognized 
by cell surface receptors inducing in this way endocytosis. Important to mention, 
high intensity luminescence from the vesicles might be explained on the basis of 
the acidic internal pH. The cytosol luminescence is unambiguously due to the 
internalization of the whole organotin complex; we infer that because the free 
ligand showed lack of staining under the same condition.  
 
Interestingly, none of the compounds is able to get into and stain the nucleus, 
which suggests the dissociation of the chelating ligand and then producing the 
intermediate R2Sn2+,xxxvi  which causes the high cytotoxicity. The role of ligands 
is of considerable importance in tuning the cytotoxic characteristics of the 
complex. Ligands can modify the reactivity, lipophilicity, oral/systematic 
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bioavailability of metal ions, stabilization of the oxidation state and substitutional 
inertness depending on the requirements for chemotherapy. xxxvii  ,xxxviii  
  
Now it is generally accepted that organotin(IV) moieties may bind to 
glycoproteins or to cellular proteins, and directly interact with DNA, causing cell 
death by apoptotic mechanisms. xxxix  
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6. CONCLUSIONS 
 
In summary, we have synthesized four new organotin compounds 
derivative from Schiff bases in good yields. 
 
The results of the cytotoxic selectivity assay, indicates that the compounds 
are not selective when using two human tissue cultures of normal (HGF1, 
gingival biopsy) and cancer cells (A-375, melanoma cells), in both of the cultures 
follows the same toxicity tendency. 
 
Cytotoxic assays with melanoma murine cells B16F10, shows that 
compound 2, does not have any toxic activity, even with the highest 
concentration. Compounds 1, 3 and 4 has a good cytotoxic capacity at 10 µg/ml, 
but a lower concentrations compound 1 and 4 presents better cytotoxicity.  
 
The cytotoxicity comparison between the ligands and compounds, suggest 
that the ligand has no influence on the toxic capacity, while the organotin moiety 
is crucial for cytotoxicity. 
 
Comparing compound 1 and 4 with metal based commercial drugs, like 
cisplatin and carboplatin proved in the same tissue culture (B16F10, melanoma 
murine cells), compound 1 at concentration of 1 µg/ml, almost has the same 
toxicity that cisplatin (IC50: 1.26 µg/ml), and it is nearly the half amount that 
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carboplatin needs to inhibit the 50% of cell growth. Compound 4 has a very 
good toxic capacity at 2.5 µg/ml, with less than 20% of viability, compared with 
carboplatin (IC50: 2.33 µg/ml).  
 
The cell images shows very strong cytoplasmic staining in the cells with 
numerous vesicle-like structures which suggests that the possible internalization 
mechanism of the organotin compounds is endocytosis. 
 
The cytosol luminescence is unambiguously due to the internalization of 
organotin complex; we infer that because the free ligand showed lack of staining 
under the same condition.  
 
No one of the compounds is able to get into and stain the nuclei, which 
suggests the dissociation of the chelating ligand and then producing the 
intermediate R2Sn2+, which causes the high cytotoxicity. The intermediate 
Ph2Sn2+ , (compound 1 and 4 )has the best cytotoxic behavior. 
 
The results obtained in this work contribute to the tin cytotoxic capacity 
knowledge, and know some more about the behavior in cells. 
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6.1 Perspectives 
 
As part of the knowledge generated in this research work was 
demonstrated that tin compounds derivative from salicylidene bezoylhydrazones 
have good cytotoxic properties, and that the ligand plays an important role in the 
behavior of the molecule. Studies with other cells lines are required to evaluate if 
this compounds have selectivity for other kind of cancer cells. 
 
To continue with this work, we are going to carry out the synthesis of new 
molecules, whit some structural variations, to improve the cellular internalization. 
Also we could continue the study of the behavior of the molecule and the tin 
directly with the DNA using electrophoresis. 	  	  	  	  	  	  	  
 	  	  	   	  	  	  	  	  	  
	  	   63	  
	  
7.REFERENCES 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
i  M. R. Stratton, P. J. Campbell and P. A. Futreal. The cancer genome. Nature, 
2009, 458, 719-724. 
 
 
ii  WHO.Cancer [http://www.who.int/mediacentre/factsheets/fs297/es/] 
 
 
iii  ACS. Gobal cáncer facts and figures 2007. 
[http://www.cancer.org/acs/groups/content/@nho/documents/document/globalfa
ctsandfigures2007rev2p.pdf] 
 
 
iv M. Hernández Menéndez, M. Ríos Hernández. Oncogenes y cáncer. Instituto 
Nacional de Oncología y Radiobiología. Rev Cubana Oncol 1999, 15(2),131-9. 
 
 
v ECO. Generalidades en oncología. 
[http://www.fundacioneco.es/images/stories/ECO/AsistenciaAlPaciente/Informac
ionTumores/1.Generalidades.pdf] 
 
 
vi A. Alama, B. Tasso, F. Novelli and F. Sparatore. Organometallic compounds in 
oncology: implications of novel organotins as antitumor agents. Drug Discovery 
Today, 2009, 14, 9-10. 
 
 
vii S. Rauf, J.J. Gooding, K. Akhtar, M.A. Ghauri, M. Rahman, M.A. Anwar, A.M. 
Khalid, Electrochemical approach of anticancer drugs–DNA interaction, 
J.Pharmaceut. Biomed. Anal. , 2005, 37, 205–217. 
 
 
 
viii M. Sirajuddin , S. Ali, A. Badshah, Drug–DNA interactions and their study by 
UV–Visible, fluorescence spectroscopies and cyclic voltammetry, J. of 
	  	   64	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Photochem. and Photobiol. B: Biology, 2013, 124, 1–19. 
 
 
ix Departamento de Química Inorgánica y Nuclear, Facultad de Química, UNAM. 
Desarrollo de fármacos de base metálica Antitumorales y antiparasitarios. 
[http://www.optica.inaoep.mx/tecnologia_salud/2013/1/memorias/conferencistas/
LenaRuizAzuara_E_06_06_13.pdf] 
 
 
x K. S.Prasad, L. S. Kumar, M. Prasad, and H. D. Revanasiddappa. Novel 
Organotin(IV)-Schiff Base Complexes: Synthesis, Characterization, 
Antimicrobial Activity, and DNA Interaction Studies. Bioinorg. Chem. and Applic., 
2010, Article ID 854514, 9 pages. 
 
 
xi N. Gerasimchuk,T. Maher. Tin(IV) Cyanoximates: Synthesis, Characterization, 
and Cytotoxicity. Inorg. Chem., 2007, 46, 7268-7284. 
 
 
xii  S. H. L. Thoonen, B. J. Deelman, G. van Koten. Synthetic aspects of 
tetraorganotins and organotin(IV) halides. J. Organomet. Chem., 2004, 689, 
2145–2157. 
 
 
xiii (a) J. K. Park , W. S.  Kima, G. Otgondemberel, B. J. Lee, D. E.  Kimb, T. S. 
Kwon. Photoluminescence and electroluminescence properties of organotin (IV) 
complexes. Colloids and Surfaces A: Physicochem. Eng. Aspects, 2008, 321, 
266–270. (b) Y. Fazaeli, M. M. Amini, E. Najafi, E. Mohajerani, M. Janghouri, A. 
Jalilian, S. Weng Ng. Synthesis and Characterization of 8-hydroxyquinoline 
Complexes of Tin(IV) and Their Application in Organic Light Emitting Diode. J. 
Fluoresc., 2012, 22, 1263–1270. 
 
 
xiv  (a) K. Li, A. Tong. A new fluorescent chemosensor for Zn2+ with facile 
synthesis: “Turn-on” response in water at neutral pH and its application for live 
cell imaging. Sensors and Actuators B, 2013, 184, 248–253. (b) M. Gielen. Tin 
Chemistry: Fundamentals. Frontiers and Applications, 2008. 
 
 
	  	   65	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
xv (a) S. L. Cai , Y. Chen, W. X. Sun, H. Li, Y. Chen, S.S. Yuan. 2-, 3-, and 4-(1-
Oxo-1H-2,3-dihydroisoindol-2-yl)benzoic acids and their corresponding 
organotin carboxylates: synthesis, characterization, fluorescent, and biological 
activities. Bioorganic & Medicinal Chem. Lett., 2010, 20, 5649–5652. (b) S. M. 
Crawford, A. Al-Sheikh Ali, T. S. Cameron, and A. Thompson. Pyrrolyldipyrrinato 
Tin(IV) Complexes. Inorg. Chem., 2011, 50, 8207-8213. 
 
 
xvi  (a) L. Nagy, A. Szorcsik, K. Kovacs. Tin compounds in pharmacy and 
nutrition. Pharm. Hungarica 2000, 70, 53-71. (b) M. Nath, S. Pokharia, R. 
Yadav, Coord. Organotin(IV) complexes of amino acids and peptides. Chem. 
Rev., 2001, 215, 99-149. (c) M. Gielen, Cytotoxic, Mutagenic and Carcinogenic 
Potential of Heavy Metals Related to Human Environment. In Tin-Based 
Antitumor Drugs. NATO ASI Ser., 1997, 26, 445-455. (d) D. De Vos, R. Willem, 
M. Gielen, K. E. Van Wingerden, K. Nooter. The Development of Novel 
Organotin Anti-Tumor Drugs: Structure and Activity. Metal-Based Drugs., 1998, 
5, 179-188. (e) C. Pettinari. Organotin(IV) derivatives of imidazoles, pyrazoles 
and related pyrazolyl and imidazolyl ligands. Main Group Met. Chem., 1999, 22, 
661-692. (f) A. J. Crowe, Antitumor activity of tin compounds. In Metal 
Compounds in Cancer Therapy; Fricker, S. P., Ed.; Chapman & Hall:London, 
1994, 147-179. 
 
 
xvii  V. Chandrasekhar, R. Thirumoorthi, R. K. Metre, B. Mahanti. Steric control in 
the reactions of 3-pyrazolecarboxylic acid with diorganotin Dichlorides. J. of 
Organomet. Chem., 2011, 600-606. 
 
 
xviii  A. J. Crowe, P.J. Smith, and G. Atassi, Chem. Biol. Interact., 1980, 32, 171. 
 
 
xix G. D. Liu, J. P. Liao, Y. Z. Fang, S. S. Huang, G. L. Sheng, and R. Q. Yu, 
Analytical Sciences, 2002, 18, 391-395. 
 
 
xx  F. Arjmand, A. Jamsheera, DNA binding studies of new valine derived chiral 
complexes of tin(IV) andzirconium(IV),  Spectrochimica Acta Part A, 2011, 78, 
45–51. 
 
 
	  	   66	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
xxi A. Alama, B. Tasso, F. Novelli and F. Sparatore. Organometallic compounds 
in oncology: implications of novel organotins as antitumor agents. Drug 
Discovery Today, 2009, 14, 9-10. 
 
 
xxii  E. Katsoulakou, M. Tiliakos, G. Papaefstathiou, A. Terzis, C. Raptopoulou, G. 
Geromichalos, K. Papazisis, R. Papi, A. Pantazaki, D. Kyriakidis, P. Cordopatis, 
E. Manessi-Zoupa, Diorganotin(IV) complexes of dipeptides containing the a-
aminoisobutyryl residue (Aib), J. of Inorg. Biochem., 2008, 102, 1397–1405. 
 
 
xxiii  N. Gerasimchuk, T. Maher, P. Durham, K. V. Domasevitch, J. Wilking and A. 
Mokhir, Inorg. Chem., 2007, 46, 7268–7284. 
  
 
xxiv  A. P. Rebolledo, J. D. Ayala, C. M. Lima, N. Marchini, G. Bombieri, C. L. 
Zani, E. M. S. Fagundes and H. Beraldo, Eur. J. Med. Chem., 2005, 40, 467–
472. 
 
  
xxv  S. Rollas, G. Küçükgüzel. Biological Activities of Hydrazone Derivatives. 
Molecules 2007, 12, 1910-1939. 
 
 
xxvi  (a) F. Q. Liu,  J. T. Wang, R. J. Wang, H. G. Wang, X. K. Yao. Syntheses 
and molecular structures of complexes formed in the reaction of dichlorobis[π-
cyclopentadienyl)-dicarbonyliron]tin(IV) with polydentate o-(nuclear substituted 
α-hydroxybenzylidenehydrazonomethyl)phenols. J. Organomet. Chem. 1989,  
371, 35. (b) Z. K.  Yu, S. H.  Wang, Z. Y. Yang, X. M.  Liu, N. H. Hu, Synthesis 
and molecular structure of nBu2[(MeO)3C6H2C(O)N2CHC6H4O]Sn formed in 
the reaction of di-n-butyl(IV) oxide with 3, 4, 5-trimethoxy-benzoyl 
salicylahydrazone.  J. Organomet. Chem., 1993, 447, 189. (c) H.D. Yin, J.C. 
Cui, Y.L. Qiao, Synthesis, characterization and crystal structure of binuclear 
diorganotin(IV) complexes derived from hexadentate diacylhydrazone ligands. 
Polyhedron 2008, 27, 2157. 
 
 
xxvii  (a) W. Bansse, E. Ludwig, E. Uhlemann, H. Mehner, F. Weller, K. Dehnicke, 
Zinn(IV)-Komplexe mit dreizähnigen diaciden Liganden. Z. Anorg. Allg. Chem., 
	  	   67	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1992, 607, 177. (b) L. Labib, T. E. Khalil, M. F. Iskander, L. S. Refaat. 
Organotin(IV) complexes with tridentate ligand-IV organotin(IV) complexes with 
N-salicylidene- and N-pyridoxylideneacylhydrazines. crystal and molecular 
structure of monochloro-monomethyl [(N-salicylidene-p-
methoxybenzoylhydrazinato) ono(2)]tin(IV) methanol. Polyhedron 1996, 15, 
3697. (c) M. Hong, H.D. Yin, S.W. Chen, D.Q. Wang. Synthesis and structural 
characterization of organotin(IV) compounds derived from the self-assembly of 
hydrazone Schiff base series and various alkyltin salts. J. Organomet. Chem. 
2010, 695, 653-662. 
 
 
xxviii   A. Valdivieso Garcia, R. Clarke,  K. Rahn, A. Durette, D. MAcLeod, C. 
Gyles. Neutral Red Assay for Measurement of Quantitative Vero Cell 
Cytotoxicity. Applied and Environmental Microbiology, 1993, 59, 1981-1983. 
 
 
xxix L. Collins and S. Franzblau. Microplate Alamar Blue assay versus BACTEC 
460 system for high-throughput screening of compounds against Mycobacterium 
tuberculosis and Mycobacterium avium. Antimicrobial agents and 
chemotherapy, 1997, 41, 1004-1009. 
 
 
xxx J. Mikus, and D. Steverding. A simple colorimetric method tos creen drug 
cytotoxicity against Leishmania using the dye Alamar Blue. Parasitology 
international, 2000, 48, 265-269. 
 
 
xxxi  J. O´Brien. Investigation of the Alamar Blue (resazurin) fluorescent dye for 
the assessment of mammalian cell cytotoxicity. European J. of Biochem., 2000, 
267, 5421-5426. 
 
 
xxxii  B. Muñoz, R. Santillan, M. Rodriguez, J. Méndez, M. Romero, N- Farfán, P. 
Lacroix, K. Nakatani, G. Ramos, J. Maldonado et. al. Synthesis, cristal structure 
and non.linear optical properties of boronates derivatives of 
saliciyldeniminophenols. J. Organomet. Chem. 2008, 690, 2351- 2357. 
 
 
xxxiii  P. J. Smith. Chemical Shifts of 119Sn Nuclei in Organotin Compounds. 
Annual Reports on NMR Spectroscopy, 1978, 8, 291-370. 
	  	   68	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
xxxiv  C. García, B. Muñoz, V. Jiménez, I. Moggio, E. Arias, R. Chan, R. Santillan. 
Synthesis and photophysical characterization of organotin compoundsderived 
from Schiff bases for organic light emitting diodes. Dyes and Pigments, 2014, 
106, 188-196. 
 
 
xxxv  H. Silva, V. Barra, V. Rocha, F. Frézard, P. Lopes, S. Fontes. Novel 
platinum(II) complexes of long chain aliphatic diamine ligands with oxalato as 
the leaving group. Comparative cytotoxic activity relative to chloride precursors.  
J. Braz. Chem. Soc., 2010, 21, 10. 
 	  
xxxvi  L. Pellerito and L. Nagy, Coord. Chem. Rev., 2002, 224, 111–150 and 
references therein; (b) M. L. Falcioni, M. Pellei and R. Gabbianelli, Mutat. Res., 
2008, 653, 57–62 and references therein; (c) Q. Li, P. Yang, H. Wang and M. 
Guo, J. Inorg. Biochem., 1996, 64, 181–195; (d) J. S. Casas, E. E. Castellano, 
M. D. Couce, J. Ellena, A. Sánchez, J. L. Sánchez, J. Sordo and C. Taboada, 
Inorg. Chem., 2004, 43, 1957–1963; (e) Y. Arakawa, Biomed. Res. Trace Elem., 
2000, 11, 259–286. 
 
 
xxxvii  M. Galanski, M. A. Jakupec and B. K. Keppler, Curr. Med. Chem., 2005, 12, 
2075–2094. 
 
 
xxxviii  (a) T. Storr, K. H. Thompson and C. Orvig, Chem. Soc. Rev., 2006, 35, 
534–544; (b) W. H. Ang and P. J. Dyson, Eur. J. Inorg. Chem., 2006, 20, 4003–
4018. 
 
 
xxxix  R. Khan, S. Yadav, Z. Hussain, F. Arjmanda and S. Tabassum. 
Carbohydrate linked organotin(IV) complexes as human topoisomerase Iα 
inhibitor and their antiproliferative effects against the human carcinoma cell line. 
Dalton Trans., 2014, 43, 2534. 
 	  	  	  
	  	   69	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
 
8. APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
APENDIX A 
 
 
CHARACTERIZATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   70	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H -NMR (400 MHz, CDCl3) spectrum of compound 1. 
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13C-NMR (100 MHz, CDCl3) spectrum of compound 1. 
 
 
 
 
119Sn-NMR (149.14 MHz, CDCl3) spectrum of compound 1. 
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1H/1H COSY spectrum of compound 1 (aromatic region). 
 
 
 
 
1H/13C HETCOR spectrum of compound 1 (aromatic region). 
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1H-NMR (400 MHz, CDCl3) spectrum of compound 2. 
 
 
 
 
13C-NMR (100 MHz, CDCl3) spectrum of compound 2. 
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119Sn-NMR (149.14 MHz, CDCl3) spectrum of compound 2. 
 
 
 
 
1H/1H COSY spectrum of compound 2 (aromatic region). 
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1H/13C HETCOR spectrum of compound 2 (aromatic region). 
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1H-NMR (400 MHz, CDCl3) spectrum of compound 3. 
 
 
 
 
13C-NMR (100 MHz, CDCl3) spectrum of compound 3. 
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119Sn -NMR (149.14 MHz, CDCl3) spectrum of compound 3. 
 
 
 
 
1H/1H COSY spectrum of compound 3 (alifatic region). 
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1H/1H COSY spectrum of compound 3 (aromatic region). 
 
 
 
 
1H/13C HETCOR spectrum of compound 3 (alifatic region). 
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1H/13C HETCOR spectrum of compound 3 (aromatic region). 
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1H-NMR (400 MHz, DMSO-d6) spectrum of compound 4. 
 
 
 
 
13C-NMR (100 MHz, DMSO) spectrum of compound 4. 
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119Sn -NMR(149.14 MHz, DMSO) spectrum of compound 4. 	  	  
	  
1H/1H COSY spectrum of compound 4 (aromatic region). 	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IR  spectrum of compound 1 	  
	  
IR  spectrum of compound 2 
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IR  spectrum of compound 3 	  
	  
IR  spectrum of compound 4 
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Mass  spectrum of compound 1 
 
 
 
Mass  spectrum of compound 2 
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Mass  spectrum of compound 3 
 
 
Mass  spectrum of compound 4 
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Packing structure of compound 1 	  	  	  
	  
Packing structure of compound 2 	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Packing structure of compound 4 	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Confocal microscopy of melanoma                 Confocal microscopy of melanoma  
cells B16F10 untreated                                              cells B16F10 with DMSO 
(control).                                                            (control). 	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Confocal microscopy of melanoma                 Confocal microscopy of melanoma  
cells B16F10 treated with Ligand 1	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(10 µg /ml).                                                           (10 µg /ml).	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Confocal microscopy of melanoma                 Confocal microscopy of melanoma  
cells B16F10 treated with Ligand 3 y 4                   cells B16F10 treated with  
(10 µg /ml).                                                           compound 1 (10 µg /ml).                                  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Confocal microscopy of melanoma                 Confocal microscopy of melanoma  
cells B16F10 treated with                               cells B16F10 treated with 	  
compound 2 (10 µg /ml).                                    compound 3 (10 µg /ml).	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Confocal microscopy of melanoma 
cells B16F10 treated with 
compound 4 (10 µg /ml). 
 
 
 	  	  
	  	  
Compounds 1-4 in chloroform. (UV-365nm) 
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